Top 5 Stocks to Buy Now
→ Elon Is Quietly Doubling Down on This Bizarre Asset (From Brownstone Research) (Ad)tc pixel
NASDAQ:LYRA

Lyra Therapeutics Q1 2026 Earnings Report

Lyra Therapeutics logo
$0.58 +0.02 (+4.11%)
As of 10:05 AM Eastern
ProfileEarnings HistoryForecast

Lyra Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$1.36
Beat/Miss
N/A
One Year Ago EPS
N/A

Lyra Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Lyra Therapeutics Announcement Details

Quarter
Q1 2026
Date
5/12/2026
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Lyra Therapeutics Earnings Headlines

Lyra Therapeutics (NASDAQ:LYRA) Shares Up 6.2% - Here's Why
June 17, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30843601
Lyra Therapeutics Ends Major Office Sublease Agreement
April 17, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/lyra-therapeutics-ends-major-office-sublease-agreement?utm_source=marketbeat.com&utm_medium=referral
Solar is dead. Here’s what replaces it.
Starting July 4th, every new solar and wind project in America loses its federal tax credits. But one zero-carbon energy source retains full government backing for eight more years - and it runs around the clock without batteries. Investment in this sector has surged 100x in seven years. The Pentagon named it a top energy priority, California mandated it, and Google, Meta, and Berkshire Hathaway are already under contract. One company controls the entire chain from the ground to the grid.tc pixel
June 24 at 1:00 AM  |  Behind the Markets (Ad)
Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC
April 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/17/3276116/0/en/lyra-therapeutics-inc-announces-intention-to-voluntarily-file-form-25-for-delisting-from-nasdaq-and-subsequent-deregistration-with-the-sec.html
After layoffs, Lyra Therapeutics exits Watertown and Waltham leases
April 14, 2026  |  bizjournals.comhttps://www.bizjournals.com/boston/news/2026/04/13/lyra-terminates-leases.html
Treating allergic fungal rhinosinusitis in children
April 8, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/treating-allergic-fungal-rhinosinusitis-in-children/ar-AA20r233
See More Lyra Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lyra Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lyra Therapeutics and other key companies, straight to your email.

About Lyra Therapeutics

Lyra Therapeutics (NASDAQ:LYRA) is a clinical-stage biopharmaceutical company dedicated to developing targeted drug delivery therapies for diseases of the ear, nose and throat (ENT). Leveraging its proprietary Therapeutic Drug Delivery (TDD) platform, the company designs bioresorbable, steroid-eluting implants that provide sustained, localized release of medication directly to affected tissue. This approach aims to improve patient outcomes by reducing the need for repeated administration and minimizing systemic side effects.

The company’s lead product candidate, LYR-210, is an implantable matrix that delivers the corticosteroid mometasone furoate over several months to treat chronic rhinosinusitis (CRS). LYR-210 is currently advancing through pivotal Phase 3 clinical trials, following positive Phase 2 data demonstrating significant improvements in symptom control and quality of life measures. In addition, Lyra is developing LYR-220 for chronic obstructive pulmonary disease (COPD) and exploring other respiratory indications, all based on its sustained-release implant technology.

Founded in 2015 and headquartered in Lynnfield, Massachusetts, Lyra Therapeutics operates research and development facilities in the United States. The company is led by President and Chief Executive Officer Bryan J. Bork, supported by a management team with extensive expertise in drug delivery, drug development and regulatory strategy. As Lyra advances its pipeline through clinical development, it seeks to establish partnerships for commercial manufacturing and expand its platform into additional ENT and respiratory disease areas.

View Lyra Therapeutics Profile
Earnings Tools